Background
==========

Cerebral hemorrhage is a common complication of cancer \[[@b1-medscimonit-22-1716],[@b2-medscimonit-22-1716]\]. Recent studies showed that the risk of cerebral hemorrhage is quite high in cancer patients \[[@b3-medscimonit-22-1716]\[, indicating that cancer itself can directly or indirectly lead to the development of cerebral hemorrhage; therefore, we define this complication as cancer-related cerebral hemorrhage \[[@b4-medscimonit-22-1716],[@b5-medscimonit-22-1716]\]. Furthermore, recent evidence shows that hypertension is rare in patients with cancer-related cerebral hemorrhage. Cerebral hemorrhage is usually caused when bleeding develops in the brain tumor due to metastatic cancer, cancer-related coagulation disorders, and adverse effects of cancer-related treatments \[[@b4-medscimonit-22-1716],[@b6-medscimonit-22-1716]--[@b8-medscimonit-22-1716]\]. However, there are complicated situations, such as the development of different cell types, their growth phases, and intracranial metastasis; these complications might enhance the manifestation of a variety of clinical features of cancer, including cerebral hemorrhage \[[@b9-medscimonit-22-1716],[@b10-medscimonit-22-1716]\].

Liver cancer is a common malignancy with poor prognosis. It is the sixth most commonly occurring cancer in the world and the third most frequent cause of cancer mortality \[[@b11-medscimonit-22-1716]\]. The highest incidence rates of liv**e**r cancer have been reported in Asia and Africa. Approximately 85% of all liver cancers occur in these areas \[[@b12-medscimonit-22-1716]\]. Metastases of liver cancer are common; however, there are rare cases in which patients develop brain metastases from hepatocellular carcinoma. It is noteworthy that patients with liver cancer can also develop complications of cerebral hemorrhage \[[@b3-medscimonit-22-1716],[@b13-medscimonit-22-1716]--[@b16-medscimonit-22-1716]\] or hematomas \[[@b17-medscimonit-22-1716]\]. On some occasions, intracerebral hemorrhage is the first presentation of brain metastatic primary clear cell carcinoma of the liver \[[@b18-medscimonit-22-1716],[@b19-medscimonit-22-1716]\]. However, to date, no study has reported clinical features and potential pathogeneses of liver cancer accompanied by cerebral hemorrhage as a complication. The incidence of liver cancer is quite high in Guangxi Province, China, with a liver cancer mortality rate of 34.4/10 million in 2004--2005. Liver cancer has become the leading cause of cancer-related deaths in Guangxi and seriously endangered the health of local people (20). In the present study, our aim was to study the clinical features of liver cancer patients with cerebral hemorrhage in Guangxi. At the First Affiliated Hospital of Guangxi Medical University, between January 2003 and December 2014 we collected clinical data from liver cancer patients who also had the complication of cerebral hemorrhage. Furthermore, we retrospectively analyzed the clinical features of hepatic cancer patients with cerebral hemorrhage in order to improve our understanding of liver cancer.

Material and Methods
====================

Diagnosis: Inclusion and exclusion criteria
-------------------------------------------

### Diagnostic criteria

Cases were selected according to the ICD-10 standard, which is a component of an international statistical classification of diseases. In total, we recruited 11 133 liver cancer patients from the database. We obtained the data of liver cancer patients using the code C22. Thus, we searched for the data of liver cancer patients, whose condition was complicated with cerebral hemorrhage. For this purpose, we used the coding C22 and I61. The diagnostic criteria for cerebral hemorrhage are referred as the 2007 Guidelines for the Diagnosis and Treatment from the American Heart Association \[[@b21-medscimonit-22-1716]\]. The diagnosis of primary liver cancer was made according to the guidelines set by Giammarile et al. in France \[[@b22-medscimonit-22-1716]\]. The approval for medical ethics of this study was obtained from the Human Ethics Committee at our hospital.

### Inclusion criteria

Liver cancer was confirmed only by pathological diagnosis; we did not check whether each of the liver cancer cases met the criteria of clinical treatment of liver cancer. We confirmed the recurrence and metastasis of liver cancer in some cases. While treating liver cancer patients in the hospital, we came across patients with local neurological deficiency, such as sudden headache, limb weakness, numbness, and unclear speech. By performing brain CT or MRI scan and susceptibility-weighted imaging (SWI), we confirmed the presence of intracranial hemorrhage in these patients. Intracranial hemorrhage was diagnosed in the initial stages in these patients. These patients developed neurological symptoms due to intracranial hemorrhage. We hospitalized the patients who had developed intracranial hemorrhage. Then, we diagnosed liver cancer in these patients for the first time. A panel of an oncologist, neurologist, and neuroimaging experts worked together to recruit patients in this study.

### Exclusion criteria

We excluded patients who developed cancer in other systems of the human body. We also excluded patients who developed the complication of cerebral infarction. We excluded liver cancer patients who had developed cerebral hemorrhage after 5 years of diagnosis. We did not find any patients showing evidence of recurrence or metastasis of non-active liver cancer. Finally, we excluded patients that did not have sufficient clinical data.

Collection of clinical materials
--------------------------------

We collected the following data: demographic characteristics, including age and sex; traditional risk factors such as diabetes, hypertension, high cholesterol, and stroke; liver cancer-related data such as pathological types of cancer cells and metastasis; and treatment methods. We also included the following data related to acute cerebral hemorrhage: main symptoms, signs, severity of neurological functions, and consciousness. The National Institute of Health Stroke Scale (NIHSS) was used for evaluating the severity of neurological functions. The Glasgow coma scale (GCS) was used to evaluate the level of consciousness. To reduce the effect of progression of liver cancer on physical activities of patients, we included a modified Rankin scale (mRS) and evaluated the prognosis of patients at 30 days after they had been diagnosed with cerebral hemorrhage. mRS scores \>3 indicated poor prognosis. We collected the results of routine blood tests, blood biochemistry tests, coagulation indexes, D-dimer, tumor markers, electrocardiography (ECG), cardiac color Doppler ultrasound, cervical blood Doppler, CT angiography (CTA), brain CT, brain magnetic resonance image (MRI), and magnetic resonance angiography (MRA). According to a research study conducted by Navi et al., \[[@b7-medscimonit-22-1716]\] on cerebral hemorrhage, coagulation dysfunctions were present in the patient if any of the parameters met the following criteria: platelet \<100×10^9^/L, International Normalized Ratio (INR) \>1.5, activated partial thromboplastin time (APTT) \>45 s, prothrombin time (PT) \>15s, disseminated intravascular coagulation (DIC): fibronectin \<2 g/L, and D-dimer \>290 ng/dL.

Results
=======

In the present study, we selected a total of 11 133 patients with liver cancer. Among them, there were 9 patients (0.08%) who met the criteria for liver cancer and cerebral hemorrhage, including 3 females and 6 males, with an age range of 48--73 years. The average age of these patients was in the range of 61.67±8.97 years. We diagnosed liver cancer in all 9 patients. Among them, 3 patients had developed metastasis in the lymph nodes of their armpit, and they had also developed secondary metastasis in the distant tissues from the primary liver and lungs tumors. Interestingly, no metastasis had developed in the brain before the development of cerebral hemorrhage, which seemed to be a complication of liver cancer. According to blood biochemistry tests, 6 patients had abnormal liver function. Furthermore, coagulation dysfunction was detected in 8 patients, including 1 with disseminated intravascular coagulation (DIC). Nine had elevated tumor markers, 6 had increased alpha-fetoprotein (AFP) level, 5 had increased cancer antigen (CA125) level, 5 had elevated CA199 level, 3 had increased CA153 level, and 4 had elevated levels of carcinoembryonic antigen (CEA).

According to the results of hepatic cancer treatment, there were 2 patients who received hepatectomy and chemotherapy. Furthermore, 1 patient received simple chemotherapy, while the remaining patients did not continue with cancer treatments ([Table 1](#t1-medscimonit-22-1716){ref-type="table"}).

Among the 9 patients recruited in this study, 4 (44.44%) had a history of hypertension. The remaining 5 had no traditional stroke risk factors such as hypertension, high cholesterol, diabetes, smoking, or drinking history. The onset of cerebral hemorrhage was characterized by the following symptoms: acute clinical presentation such as sudden headache, disturbance of consciousness, limb weakness, and unclear speech. Cerebral hemorrhage developed in 4 patients receiving treatment for liver cancer; 1 developed cerebral hemorrhage at 1 month after the diagnosis of liver cancer, and 3 developed cerebral hemorrhage after approximately 1 year (11, 12, and 13months) after being diagnosed with liver cancer. The remaining 5 were hospitalized when they developed cerebral hemorrhage. Liver cancer was subsequently detected for the first time in these 5 patients. Most hemorrhages occurred in the cerebral area (5 patients) ([Figure 1](#f1-medscimonit-22-1716){ref-type="fig"}); however, there were 3 patients that developed hemorrhage in the basal ganglion. Furthermore, we found only 1 patient who developed hemorrhage in the brain stem. All 5 patients with cerebral hemorrhage became comatose, with coma severity in the range of 5--8 on the GCS. According to the NIHSS, the scores were in the range of 1--4 in 4 patients with full consciousness. Twenty-one days after the patients had cerebral hemorrhage, we again performed brain CT and confirmed that lesion signals within the brain were consistent with cerebral hemorrhage-related changes. Moreover, we did not observe any intracerebral tumor or cerebral metastasis in patients with liver cancer. None of the patients received anti-platelet or anti-coagulation treatments. All the patients received conservative treatment, but in 1 patient we performed drilling drainage. Thirty days after cerebral hemorrhage, mRS was in the range 0--4 in 4 patients and 6 in 1 patient, who died. The results are summarized in [Table 2](#t2-medscimonit-22-1716){ref-type="table"}.

Discussion
==========

Clinical features of liver cancer complicated with cerebral hemorrhage
----------------------------------------------------------------------

In the present study, only 0.08% of liver cancer patients developed cerebral hemorrhage despite receiving treatment for liver cancer at the hospital. In all these patients, cerebral hemorrhage developed approximately 1 year (365 days) after their diagnosis of liver cancer was confirmed. The correlation of timing between the occurrence of cerebral hemorrhage and the diagnosis of liver cancer was roughly consistent, indicating that the occurrence of cerebral hemorrhage in liver cancer patients should have the same features of occurrence as other types of cancer. It is worth noting that 5 patients were hospitalized and treated for cerebral hemorrhage; in these patients, liver cancer was diagnosed for the first time during their course of treatment. This indicates that cerebral hemorrhage is the first manifestation of symptoms in some patients with liver cancer. This is in good agreement with previous reports establishing that cerebral infarction is the first manifestation of liver cancer in some patients \[[@b23-medscimonit-22-1716]--[@b25-medscimonit-22-1716]\]. However, cerebral hemorrhage is the first manifestation in a very few liver cancer patients.

Cerebral hemorrhage is one of the complications of the central nervous system in patients with liver cancer. However, it is worth exploring whether cancer increases the risks of cerebral hemorrhage. In 2012, Zöller et al. \[[@b5-medscimonit-22-1716]\] collected cancer data between from 1987 to 2008 in Sweden on a national level. They calculated the risk of cerebral hemorrhage in cancer patients based on Sweden's national population. The results indicated that the incidence of cerebral hemorrhage within 6 months, 6 months to 1 year, and 1 year to 5 years was 2.2%, 1.4%, and 1.3%, respectively. This indicates that the risk of cerebral hemorrhage in cancer patients is significantly higher than that in the healthy population. Similarly, the results indicate that the risk of cerebral hemorrhage increases in patients with liver cancer. In particular, cerebral hemorrhage develops within about 6 months after the diagnosis of liver cancer, as confirmed in these patients.

There are some characteristic features in liver cancer patients who developed cerebral hemorrhage. Zhang et al. \[[@b4-medscimonit-22-1716]\] retrospectively reviewed the clinical data of 69 cancer patients who had developed the complication of stroke from January 1999 to December 2004, including 13 cancer patients who had developed the complication of cerebral hemorrhage. We found that the most common site of hemorrhage was in the lobes of the brain (8 patients, 61.5%), and the prognosis of most patients was poor. In the present study, no particular signs were observed in the hemorrhage lesion site when we performed brain CT of these patients. However, we found that 1 or more tumor markers were elevated in the plasma of all patients. Most of these patients had abnormal levels of coagulation and liver function. These were the significant clinical features of these patients.

Pathogenesis of hepatic cancer with cerebral hemorrhage
-------------------------------------------------------

The pathogenesis of cerebral hemorrhage is very complicated, and we still do not know whether the pathogenesis of liver cancer and cerebral hemorrhage is related to cancer or not. This is a pertinent issue that needs to be resolved. Navi et al.4\[[@b7-medscimonit-22-1716]\] investigated 208 cancer patients with intracranial hemorrhage in Memorial Sloan-Kettering cancer center from 2000 to 2007 analyzing the causes and prognosis of these patients. The results indicated that 141 patients had non-hematological system cancer, which was complicated with cerebral hemorrhage. Among them, 98 (69.50%) patients had developed bleeding due to brain metastasis; 55 (39.01%) had coagulation dysfunctions, and 33 (23.40%) had developed bleeding within the tumor along with coagulation dysfunctions. This indicates that intracranial metastasis and coagulation dysfunctions are the common characteristics of cancer patients with cerebral hemorrhage. Their study also proved that there were other uncommon causes of cancer with cerebral hemorrhage. This included 9 patients (6.38%) with hypertensive cerebral hemorrhage, 6 (4.26%) with traumatic cerebral hemorrhage, 4 (2.84%) with cerebral hemorrhage after cerebral infarction, and 3 (2.13%) with cerebral artery aneurysms. Cerebral hemorrhage was caused by cerebral venous thrombosis in only 1 patient (0.71%). These results indicate the pathogenesis of cancer with cerebral hemorrhage is indeed a complicated issue. In the present study, there were only 2 patients with hypertension (patients \#4 and \#5) and 5 did not have any risk of developing stroke (patients \#2, \#3, \#6, \#7, and \#8). However, blood biochemistry tests showed that 8 patients had coagulation dysfunctions, indicating that coagulation dysfunctions might be the main cause of liver cancer with cerebral hemorrhage. Previous research proved that in patients with liver cancer, coagulation dysfunctions are mainly caused by a reduction in the number of platelets and clotting factors, activation of the fibrinolytic system, and extensive DIC \[[@b13-medscimonit-22-1716]--[@b15-medscimonit-22-1716]\]. Moreover, some common chemotherapy drugs, such as bleomycin, mitomycin C, and cytarabine, might aggravate coagulation dysfunctions \[[@b26-medscimonit-22-1716]--[@b28-medscimonit-22-1716]\].

In the present study, we hospitalized 5 patients who developed cerebral hemorrhage. Interestingly, the traditional risk factors for cerebral hemorrhage were never found in 2 out of 5 patients. Furthermore, liver cancer was diagnosed during their course of treatment. Nevertheless, coagulation functions were abnormal, and the level of tumor markers such as AFP was elevated in the plasma. Thus, we found further evidence to ascertain the relevant factors causing cerebral hemorrhage. Although there was no imaging to prove that brain metastasis from liver cancer does not occur prior to cerebral hemorrhage, we could not exclude the possibility of bleeding caused by brain metastasis of liver cancer. Previous research proved that when brain CT and MRI of patients showed various signs, such as strengthening effect around a hematoma, various densities within a hematoma, delayed progression of hematoma, reduction or lack of hemosiderin, and continuous swelling surrounding a hematoma, we deduced that the patient had developed intracranial tumor hemorrhage \[[@b29-medscimonit-22-1716]--[@b31-medscimonit-22-1716]\].

This was a retrospective study; therefore, we recruited a limited number of patients. The clinical data of hospitalized patients only met the criteria of clinical diagnosis. All these confounding factors are limitations in our study investigating the clinical features and pathogenesis of liver cancer patients who suffer cerebral hemorrhage as a complication. Therefore, a prospective study must be conducted in a multicenter community setting of this population. With this novel approach, we can comprehensively decipher the pathogenesis of liver cancer complicated by cerebral hemorrhage. Thus, we can devise various therapeutic treatments that are appropriate for managing this condition.

Conclusions
===========

This study describes theunique pathophysiology and clinical features of patients who have liver cancer complicated with cerebral hemorrhage. Coagulopathy cause most cerebral hemorrhage in patients with liver cancer, whereas hypertension and other causes typical in the general community are rare.The site of cerebral hemorrhage is often detected in the lobes of the brain and the prognosis is generally poor.
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![CT images showing cerebral hemorrhage. (**A1--A3**) Patient \#5 with traditional risk factors of cerebral hemorrhage; the patient was hospitalized as soon as cerebral hemorrhage was detected. Subsequently, liver cancer was detected in this patient at 1 day after admission. CT images showed that a cerebral hemorrhage had developed at the left basal ganglion. (**B1--B3**) Patient \#7 did not have any traditional risk factors of cerebral hemorrhage; however, 12 months after the diagnosis of liver cancer, the patient developed cerebral hemorrhage. A CT scan showed that a cerebral hemorrhage had developed in the left parietal lobe. (**C1--C3**) Patient \#8 also did not have any traditional risk factors for cerebral hemorrhage. The patient was hospitalized due to cerebral hemorrhage and was diagnosed with liver cancer 6 days after admission. A CT scan showed that a cerebral hemorrhage occurred at the left occipital lobe.](medscimonit-22-1716-g001){#f1-medscimonit-22-1716}

###### 

Clinical materials of 9 patients.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Number   Gender   Age   Types of tumor   Metastasis                            Cancer treatment prior to cerebral hemorhage                                Blood tests       Coagulation functions   Liver function tests   Tumor markers
  -------- -------- ----- ---------------- ------------------------------------- --------------------------------------------------------------------------- ----------------- ----------------------- ---------------------- ----------------
  1        Male     70    Hepatic cancer   No                                    Give up                                                                     PLT 37×10^9^      APTT 44.9\              ALT 51\                AFP: 5.15\
                                                                                                                                                                               PT 21.92\               AST 163\               CA125 352.6\
                                                                                                                                                                               TT 9.27\                ALB 23.7\              CA153 42.10\
                                                                                                                                                                               INR 2.26\               TBil 112.4\            CA199 1132\
                                                                                                                                                                               FIB 6.33\               DBil 50.8              CEA 5.01
                                                                                                                                                                               D-dimer 83.30                                  

  2        Male     48    Hepatic cancer   No                                    Surgery + chemotherapy[a](#tfn1-medscimonit-22-1716){ref-type="table-fn"}   PLT 228×10^9^     APTT50\                 ALT 109\               AFP 12.72\
                                                                                                                                                                               PT 15.6\                AST 77.00\             CA125 154.47\
                                                                                                                                                                               TT \>120\               TP 71.0\               CA153 13.24\
                                                                                                                                                                               INR 1.04\               TBil 13.4\             CEA 7.32
                                                                                                                                                                               FIB3.44\                DBil 20.2\             
                                                                                                                                                                               D-dimer 226.14          ALB 36.00              

  3        Female   51    Hepatic cancer   Metastasis of lymph nodes of armpit   Give up                                                                     PLT 262.4×10^9^   APTT48.2\               ALT 8\                 AFP 6.54\
                                                                                                                                                                               PT26.8\                 AST 17 T\              CA199 21.11\
                                                                                                                                                                               TT 2.78\                P67.5\                 CA125 15.07\
                                                                                                                                                                               INR 0.9\                TBil 10.3\             CA153 178.25
                                                                                                                                                                               FIB7.02\                DBil 4.2\              
                                                                                                                                                                               D-dimer 30.82           Alb 37.9               

  4        Male     65    Hepatic cancer   Metastasis within the liver           Give up                                                                     PLT 353×10^9^     APTT 32.2\              ALT 66\                AFP 3000\
                                                                                                                                                                               PT 10.8\                AST 89\                CA125 143.13\
                                                                                                                                                                               TT 5.6 INR0.75\         TP63.3\                CA153 21.0544\
                                                                                                                                                                               FIB 3.43\               TBil 47.5\             CA199 26.01\
                                                                                                                                                                               D-dimer 107.04          DBil 20.2\             CEA 0.42
                                                                                                                                                                                                       ALB 26.2               

  5        Male     57    Hepatic cancer   No                                    Give up                                                                     PLT 144×10^9^     APTT50.2\               ALT 37\                AFP 46.6\
                                                                                                                                                                               PT 19.08\               AST 63\                CA125 114.03\
                                                                                                                                                                               TT 12 INR 1.28\         TP 60.3\               CA153 19.05\
                                                                                                                                                                               FIB 2.68\               TBil 12.4\             CA199 46.93\
                                                                                                                                                                               D-dimer 112.44          DBil 5.6\              CEA 3.45
                                                                                                                                                                                                       ALB34                  

  6        Male     56    Hepatic cancer   Lung                                  Chemotherapy[b](#tfn2-medscimonit-22-1716){ref-type="table-fn"}             PLT 19×10^9^      APTT 48.9\              ALT 44\                CA125 \>600\
                                                                                                                                                                               PT 30.64\               AST 191\               CA153 34.2\
                                                                                                                                                                               TT 11.2INR 1.89\        TP 79\                 CA199 341.15\
                                                                                                                                                                               FIB 1.4\                Tbil 365\              AFP \>35350
                                                                                                                                                                               D-dimer 1283.57         Dbil 187.6\            
                                                                                                                                                                                                       ALB 22                 

  7        Female   70    Hepatic cancer   No                                    Surgery + Chemotherapy[c](#tfn3-medscimonit-22-1716){ref-type="table-fn"}   PLT 222×10^9^     APTT54.9\               ALT 21\                AFP 21.6\
                                                                                                                                                                               PT 24.95\               AST 36\                CA125 106.03\
                                                                                                                                                                               TT 9.78INR 1.06\        TP 75\                 CA153 19.95\
                                                                                                                                                                               FIB 5.12\               TBil 20.3\             CA199 46.93\
                                                                                                                                                                               D-dimer 34.37           DBil 5.0\              CEA 3.45
                                                                                                                                                                                                       ALB28                  

  8        Female   73    Hepatic cancer   No                                    Give up                                                                     PLT 143.6×10^9^   APTT 42.8 PT 34.85\     AST 36\                AFP 1898\
                                                                                                                                                                               TT 7.8\                 ALT 17.9\              CA125 829.58\
                                                                                                                                                                               INR3.36\                TP 68\                 CA153 21.07\
                                                                                                                                                                               FIB 5.19\               TBil 18.9\             CA199 38.16\
                                                                                                                                                                               D-dimer 56.16           Dbil 3.7\              CEA 5.15
                                                                                                                                                                                                       ALB 39                 

  9        Male     65    Hepatic cancer   No                                    Give up                                                                     PLT 147×10^9^     APTT 34.9\              AST 57\                AFP 6.85\
                                                                                                                                                                               PT 26.95\               ALT 19\                CA125 165.58\
                                                                                                                                                                               TT 10.45\               TP 81\                 CA153 19.12\
                                                                                                                                                                               INR3.47\                TBil 18.9\             CA199 1.46\
                                                                                                                                                                               FIB 3.51\               Dbil 97.7\             CEA 5.79
                                                                                                                                                                               D-dimer 322.02          ALB 31.8               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NB -- fluorouracil; Cisplatin;

fluorouracil, Gemcitabine, mitomycin C;

fluorouracil, Epirubicin, interferon.

PLT -- platelet (100\~300×10^9^/L); APTT -- activated partial thromboplastin time (23\~45 s); PT -- Prothrombin time (9\~15 s); TT -- thrombin time (9\~154s); D-dimer (\<290 ng/dL); INR -- International Normalized Ratio (0.8\~1.4); FIB -- fibrinogen (2\~5 g/L); TBil -- total bilirubintotal bilirubin (3\~22 μmol/L); DBil -- direct bilirubin (0\~6 μmol/L); TP -- total protein (60\~83 g/L); ALB -- albumin (35\~55 g/L); AST -- glutamic-oxalacetic transaminase (8\~45 U/L); ALT -- glutamic-pyruvic transaminase (5\~40 U/L); AFP -- alpha-fetoprotein (0\~7 ng/ml); CA -- cancer antigen: CA125: (0\~35 U/ml); CA199: (0\~27 U/ml), CA153: (0\~25 U/ml); CEA -- carcinoembryonic antigen (0\~5 ng/ml).

###### 

Clinical data of cerebral hemorrhage in 9 patients.

  Number   Gender   Age (year)   Bleeding time (day)   Traditional risk factors                               Main clinical presentations                                 Site of cerebral hemorrhage on brain CT   NIHSS or GCS (scale)   mRS (scale)
  -------- -------- ------------ --------------------- ------------------------------------------------------ ----------------------------------------------------------- ----------------------------------------- ---------------------- -------------
  1        Male     70           −1                    A history of Cerebral infarction                       Fever, disturbance of consciousness                         Left parietal lobe                        GCS 8                  5
  2        Male     48           335                   N                                                      Sudden limb weakness, loss of speech, vomit                 Left temporoparietal lobe                 GCS 5                  4
  3        Female   51           −15                   N                                                      dizziness                                                   Basal ganglion                            NIHSS 1                0
  4        Male     65           20                    High cholesterol, hypertension, smoking and drinking   Sudden seizure, dizziness, limb weakness                    Right temporal lobe                       NIHSS 2                0
  5        Male     57           −1                    Hypertension, cerebral hemorrhage                      Unclear consciousness, vomit                                Left thalamus                             GCS 7                  3
  6        Male     56           395                   N                                                      Sudden coma                                                 Pons                                      GCS 6                  6
  7        Female   70           365                   N                                                      Sudden fall, disturbance of consciousness and no response   Left parietal lobe                        GCS 8                  3
  8        Female   73           −6 d                  N                                                      sudden headache, vomit                                      Left occipital lobe                       NIHSS 1                0
  9        Male     65           −11 d                 Smoking drinking                                       Left limb weakness                                          Right basal ganglion                      NIHSS 4                1

NB -- time of hemorrhage was duration between cerebral hemorrhage and diagnosis of liver cancer, the day of diagnosis of liver cancer is recorded as zero, positive days means that cerebral hemorrhage occurred after the diagnosis of liver cancer; Negative days means that cerebral hemorrhage occurred before the diagnosis of liver cancer; N -- no traditional risk factors.
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